Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452540 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis
A Phase 2 study, sponsored by Afimmune.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03452540 is a Phase 2 study that was terminated before completion, run by Afimmune. The registered enrollment target is 9 participants.
The verdict
NCT03452540, a Phase 2 study, was terminated before completion, sponsored by Afimmune.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis
Interventions
- DRUG 1000mg DS102 (BID)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452540
The ClinicalTrials.gov registry entry for NCT03452540 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Afimmune, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 1000mg DS102 (BID) is the first listed.
NCT03452540 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03452540 about?
NCT03452540 is a clinical study titled "Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis". The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in adult patients with acute decompensated alcoholic hepatitis
What is the current status of trial NCT03452540?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-11-28. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT03452540?
The interventions under investigation include: 1000mg DS102 (BID) (DRUG).
Who is sponsoring clinical trial NCT03452540?
This trial is sponsored by Afimmune, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.